{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T14:12:11Z","timestamp":1789740731641,"version":"4.0.1"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Borderline personality disorder (BLPD) is a complex and debilitating psychiatric condition with high prevalence and clinical and psychosocial burden. Psychotherapy is the recommended first-line treatment but, in real-world clinical practice, most individuals with BLPD are prescribed psychotropic medications, including atypical antipsychotics. The literature suggests that second-generation antipsychotics may exert moderate effects on specific symptoms, but data remain limited and head-to-head comparisons are lacking. This prospective, naturalistic, follow-up study aimed to address this gap by comparing the efficacy and tolerability of low-dose clozapine versus aripiprazole in individuals with BLPD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Twenty-three patients were treated with either low-dose clozapine (n = 9) or aripiprazole (n = 14) based on clinical indication. Participants were assessed at hospital admission (T0), discharge (T1), and 3-month follow-up (T2) on emotional dysregulation, dissociative experiences, depressive symptoms, impulsivity, and quality of life. Treatment tolerability was evaluated at T1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Significant improvements in dissociation, depression, impulsivity, and quality of life were observed at both T1 and T2, independently of treatment group. Compared to aripiprazole, clozapine was associated with greater reductions in dissociative experiences at hospital discharge and in depressive symptoms at follow-up. Both treatments were safe and well tolerated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Our results suggest that low-dose clozapine is safe and may offer superior benefits for dissociative and depressive symptoms in patients with severe BLPD. Although further research is needed, these findings highlight the role of clozapine as a valuable pharmacological option in BLPD, particularly for patients with high clinical severity and inadequate response to other antipsychotics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/jcp.0000000000002249","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T14:00:20Z","timestamp":1789740020000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Low-Dose Clozapine Versus Aripiprazole in Borderline Personality Disorder"],"prefix":"10.1097","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7080-2578","authenticated-orcid":false,"given":"Michele Francesco","family":"D\u2019Incalci","sequence":"first","affiliation":[{"name":"School of Medicine, Vita-Salute San Raffaele University, Milan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Maria","family":"Congedo","sequence":"additional","affiliation":[{"name":"School of Medicine, Vita-Salute San Raffaele University, Milan"},{"name":"Department of Mental Health, ASL Lecce, Lecce"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0784-652X","authenticated-orcid":false,"given":"Giulia","family":"Agostoni","sequence":"additional","affiliation":[{"name":"Schizophrenia Research and Clinical Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0510-8275","authenticated-orcid":false,"given":"Margherita","family":"Bechi","sequence":"additional","affiliation":[{"name":"Schizophrenia Research and Clinical Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Lanzano","sequence":"additional","affiliation":[{"name":"School of Medicine, Vita-Salute San Raffaele University, Milan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Cocchi","sequence":"additional","affiliation":[{"name":"Schizophrenia Research and Clinical Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Guglielmino","sequence":"additional","affiliation":[{"name":"Schizophrenia Research and Clinical Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Spangaro","sequence":"additional","affiliation":[{"name":"Schizophrenia Research and Clinical Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Cavallaro","sequence":"additional","affiliation":[{"name":"School of Medicine, Vita-Salute San Raffaele University, Milan"},{"name":"Schizophrenia Research and Clinical Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Sforzini","sequence":"additional","affiliation":[{"name":"Schizophrenia Research and Clinical Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9658-2759","authenticated-orcid":false,"given":"Marta","family":"Bosia","sequence":"additional","affiliation":[{"name":"School of Medicine, Vita-Salute San Raffaele University, Milan"},{"name":"Schizophrenia Research and Clinical Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"R1-20260918","first-page":"156","article-title":"Borderline personality disorder","volume":"105","author":"Mendez-Miller","year":"2022","journal-title":"Am Fam Physician"},{"key":"R2-20260918","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1016\/S0140-6736(21)00476-1","article-title":"Borderline personality disorder","volume":"398","author":"Bohus","year":"2021","journal-title":"Lancet Lond Engl"},{"key":"R3-20260918","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/JCP.0000000000000132","article-title":"Pro re nata (as needed) psychotropic medication use in patients with borderline personality disorder and subjects with other personality disorders over 14 years of prospective follow-up","volume":"34","author":"Martinho","year":"2014","journal-title":"J Clin Psychopharmacol"},{"key":"R4-20260918","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.euroneuro.2015.03.017","article-title":"Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: a comparison with other psychiatric disorders","volume":"25","author":"Bridler","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"key":"R5-20260918","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/JCP.0000000000000232","article-title":"Rates of psychotropic medication use reported by borderline patients and axis II comparison subjects over 16 years of prospective follow-up","volume":"35","author":"Zanarini","year":"2015","journal-title":"J Clin Psychopharmacol"},{"key":"R6-20260918","doi-asserted-by":"crossref","first-page":"113556","DOI":"10.1016\/j.psychres.2020.113556","article-title":"Psychopharmacological treatment in borderline personality disorder: a pilot observational study in a real-world setting","volume":"295","author":"Magni","year":"2021","journal-title":"Psychiatry Res"},{"key":"R7-20260918","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s40263-021-00855-4","article-title":"Pharmacological treatments for borderline personality disorder: a systematic review and meta-analysis","volume":"35","author":"Gartlehner","year":"2021","journal-title":"CNS Drugs"},{"key":"R8-20260918","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/JCP.0b013e31822c1636","article-title":"Antipsychotics, antidepressants, anticonvulsants, and placebo on the symptom dimensions of borderline personality disorder: a meta-analysis of randomized controlled and open-label trials","volume":"31","author":"Vita","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"R9-20260918","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40263-023-01015-6","article-title":"Pharmacological management of borderline personality disorder and common comorbidities","volume":"37","author":"Pascual","year":"2023","journal-title":"CNS Drugs"},{"key":"R10-20260918","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/JCP.0b013e3182217a69","article-title":"Differential effectiveness of antipsychotics in borderline personality disorder: meta-analyses of placebo-controlled, randomized clinical trials on symptomatic outcome domains","volume":"31","author":"Ingenhoven","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"R11-20260918","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.2174\/1570159X19666210610092958","article-title":"Current clinical psychopharmacology in borderline personality disorder","volume":"19","author":"Del Casale","year":"2021","journal-title":"Curr Neuropharmacol"},{"key":"R12-20260918","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s11126-023-10045-8","article-title":"Efficacy and safety of aripiprazole in borderline personality disorder: a systematic review","volume":"94","author":"Valdivieso-Jim\u00e9nez","year":"2023","journal-title":"Psychiatr Q"},{"key":"R13-20260918","doi-asserted-by":"crossref","first-page":"e053943","DOI":"10.1136\/bmjopen-2021-053943","article-title":"Prescribing of antipsychotics among people with recorded personality disorder in primary care: a retrospective nationwide cohort study using The Health Improvement Network primary care database","volume":"12","author":"Hardoon","year":"2022","journal-title":"BMJ Open"},{"key":"R14-20260918","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S2215-0366(25)00098-7","article-title":"Absolute neutrophil count and adverse drug reaction monitoring during clozapine treatment: consensus guidelines from a global Delphi panel","volume":"13","author":"Siskind","year":"2026","journal-title":"Lancet Psychiatry"},{"key":"R15-20260918","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4088\/JCP.v59n0302","article-title":"Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder","volume":"59","author":"Benedetti","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"R16-20260918","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1080\/09585180110091994","article-title":"Clozapine in severe borderline personality disorder","volume":"12","author":"Swinton","year":"2001","journal-title":"J Forensic Psychiatry"},{"key":"R17-20260918","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3109\/13651501.2011.590211","article-title":"Medication for borderline personality disorder: a survey at a secure hospital","volume":"15","author":"Haw","year":"2011","journal-title":"Int J Psychiatry Clin Pract"},{"key":"R18-20260918","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1177\/104012371302500207","article-title":"A case series of clozapine for borderline personality disorder","volume":"25","author":"Frogley","year":"2013","journal-title":"Ann Clin Psychiatry"},{"key":"R19-20260918","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40479-016-0049-x","article-title":"Experiences of women in secure care who have been prescribed clozapine for borderline personality disorder","volume":"3","author":"Dickens","year":"2016","journal-title":"Borderline Personal Disord Emot Dysregulation"},{"key":"R20-20260918","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1521\/pedi_2017_31_328","article-title":"Real-world effectiveness of clozapine for borderline personality disorder: results from a 2-year mirror-image study","volume":"32","author":"Rohde","year":"2018","journal-title":"J Personal Disord"},{"key":"R21-20260918","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s00213-023-06431-6","article-title":"A systematic review of the role of clozapine for severe borderline personality disorder","volume":"240","author":"Han","year":"2023","journal-title":"Psychopharmacology (Berl)"},{"key":"R22-20260918","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1521\/pedi_2019_33_445","article-title":"Off-label use of second-generation antipsychotics in borderline personality disorder: a survey of Italian psychiatrists","volume":"35","author":"Aguglia","year":"2021","journal-title":"J Personal Disord"},{"key":"R24-20260918","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/jclp.21876","article-title":"Cultural adaptation of the difficulties in emotion regulation scale: reliability and validity of an Italian version","volume":"68","author":"Giromini","year":"2012","journal-title":"J Clin Psychol"},{"key":"R25-20260918","first-page":"179","article-title":"The Dissociative Experiences Scale: the dissociative experience of a sample of Italian students","volume":"28","author":"Mazzotti","year":"2001","journal-title":"G Ital Psicol"},{"key":"R26-20260918","first-page":"67","article-title":"Presentation of the Beck Depression Inventory-Second edition (BDI-II): confirmation of the bifactorial structure in a champion of the Italian population","volume":"12","author":"Montano","year":"2006","journal-title":"Psicoter Cogn E Comportamentale"},{"key":"R27-20260918","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/jclp.1051","article-title":"Psychometric properties of an Italian version of the Barratt Impulsiveness Scale-11 (BIS-11) in nonclinical subjects","volume":"57","author":"Fossati","year":"2001","journal-title":"J Clin Psychol"},{"key":"R28-20260918","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1017\/S1121189X00007740","article-title":"Quality of life assessment: validation of the Italian version of the WHOQOL-Brief","volume":"9","author":"De Girolamo","year":"2000","journal-title":"Epidemiol Psichiatr Soc"},{"key":"R29-20260918","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.schres.2015.07.052","article-title":"Glasgow antipsychotic side-effects scale for clozapine \u2014 development and validation of a clozapine-specific side-effects scale","volume":"168","author":"Hynes","year":"2015","journal-title":"Schizophr Res"},{"key":"R30-20260918","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1600-0447.2008.01323.x","article-title":"Pathological dissociation and neuropsychological functioning in borderline personality disorder","volume":"119","author":"Haaland","year":"2009","journal-title":"Acta Psychiatr Scand"},{"key":"R31-20260918","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1176\/appi.ajp.2017.17010025","article-title":"Dissociation in psychiatric disorders: a meta-analysis of studies using the dissociative experiences scale","volume":"175","author":"Lyssenko","year":"2018","journal-title":"Am J Psychiatry"},{"key":"R32-20260918","doi-asserted-by":"crossref","first-page":"112870","DOI":"10.1016\/j.psychres.2020.112870","article-title":"Adolescent suicide risk and experiences of dissociation in daily life","volume":"287","author":"Vine","year":"2020","journal-title":"Psychiatry Res"},{"key":"R33-20260918","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4103\/0019-5545.70989","article-title":"Treatment of severe borderline personality disorder with clozapine","volume":"52","author":"Vohra","year":"2010","journal-title":"Indian J Psychiatry"},{"key":"R34-20260918","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1177\/2045125313484323","article-title":"Clozapine for self-injurious behavior in individuals with borderline personality disorder","volume":"3","author":"Zarzar","year":"2013","journal-title":"Ther Adv Psychopharmacol"},{"key":"R35-20260918","doi-asserted-by":"crossref","first-page":"226","DOI":"10.9758\/cpn.2016.14.2.226","article-title":"Use of clozapine for borderline personality disorder: a case report","volume":"14","author":"Amamou","year":"2016","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"R36-20260918","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/JCP.0000000000000970","article-title":"Clozapine for the management of suicidal behavior in borderline personality disorder complicated by a cancer diagnosis: a case report and review of the literature","volume":"38","author":"O\u02bcLeary","year":"2018","journal-title":"J Clin Psychopharmacol"},{"key":"R37-20260918","doi-asserted-by":"crossref","first-page":"22m14587","DOI":"10.4088\/JCP.22m14587","article-title":"The protective effect of clozapine on suicide","volume":"84","author":"Lee","year":"2023","journal-title":"J Clin Psychiatry"},{"key":"R38-20260918","doi-asserted-by":"crossref","first-page":"1056050","DOI":"10.3389\/fpsyt.2022.1056050","article-title":"Factors associated with pharmacological and psychotherapy treatments adherence in patients with borderline personality disorder","volume":"13","author":"Mirhaj Mohammadabadi","year":"2022","journal-title":"Front Psychiatry"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/JCP.0000000000002249","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T14:00:24Z","timestamp":1789740024000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/JCP.0000000000002249"}},"subtitle":["A Prospective Naturalistic Study"],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":37,"URL":"https:\/\/doi.org\/10.1097\/jcp.0000000000002249","relation":{},"ISSN":["0271-0749","1533-712X"],"issn-type":[{"value":"0271-0749","type":"print"},{"value":"1533-712X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"2026-02-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}